Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients

Pediatric Neurosurgery

Volumn 41, Issue 6, 2005, Pages 292-299

  Ganigi, P M ^a   Santosh, V ^a   Anandh, B ^a   Chandramouli, B A ^a   Sastry Kolluri, V R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

bcl 2; Epidermal growth factor receptor overexpression; Immunohistochemistry; MIB 1; p53; Pediatric glioblastoma multiforme; Retinoblastoma protein; Tumor location

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADOLESCENT; ARTICLE; BRAIN REGION; CANCER SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR LOCALIZATION;

ADOLESCENT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27744458685     PISSN: 10162291     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088731     Document Type: Article

References (45)

1. Bleyer WA: Epidemiological impact of children with brain tumours. Chiles Nerv Syst 1999;15:758-763.
2. Young JL, Ries L, Silverberg E, Horon JW, Miller RW: Cancer incidence, survival and mortality for children less than 15 years. Cancer 1986;58:598-602.
3. Mainprize TG, Taylor MD, Rutka JT: Pediatric brain tumors: a contemporary prospectus. Clin Neurosurg 2000;47:259-302.
4. Armstrong DD, Giangaspero F: Pediatric brain tumors: introduction. Brain Pathol 2003;13:373-375.
5. Marchese MJ, Change CH: Malignant astrocytic gliomas in children. Cancer 1990;65:2771-2778.
6. Rickert CH, Strater R, Kaatsch P, Wassmann H, Jurgens H, Dockhorn-Dworniczak B, Paulus W: Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 2001;158:1525-1532.
7. Pollack IF: Childhood gliomas: an overview. J Neurooncol 1996;28:117-120.
8. Bhattacharjee MB, Bruner JM: p53 protein in pediatric malignant astrocytomas. A study of 21 patients. J Neurooncol 1997;32:225-233.
9. Dohrmann GJ, Farwell JR, Flannery JT: Glioblastoma in children. Neurosurgery 1975;44:442-448.
10. Kleihues P, Burger PC, Plate KH, Ohgaki H, Cavanee WK: Glioblastoma; in Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumours of the Nervous System. Lyon, IARC Press, 1997, pp 16-24.
11. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, et al: Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol 1995;13:112-123.
12. Balestrini MR, Zanette M, Micheli R, Fornani M, Solero CL, Broggi G: Hemispheric cerebral tumors in children. Long-term prognosis concerning survival rate and quality of life-considerations on a series of 64 cases operated upon. Childs Nerv Syst 1990;6:143-147.
13. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW: Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000;10:249-259.
14. Litofsky NS, Hinton D, Raffel C: The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 1994;34:967-973.
15. Felix CA, Slave I, Dunn M, Strauss EA, Phillips PC, Rorke LB, Sutton L, Bunin GR, Biegel JA: p53 gene mutations in pediatric brain tumors. Med Pediatr Oncol 1995;25:431-436.
16. Cheng Y, Ng HK, Zhang SF, Ding M, Pang JC, Zheng J, Poon WS: Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 1999;30:1284-1290.
17. Kleihues P, Louis D, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-225.
18. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavanee WK: Glioblastoma; in Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumours of the Nervous System. Lyon, IARC Press, 2000, pp 29-39.
19. Nakamura M, Konishi K, Tsunode N, Hiasa O, Tsuzaki T, Imi S, Sakaki T: Retinoblastoma protein expression and survival of patients with malignant astrocytoma. Cancer 1997;80:242-248.
20. Santiago P, Silbergeld LD: Malignant gliomas: anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, malignant oligodendroglioma; in Winn HR (ed): Youmans Neurological Surgery. Philadelphia, Saunders, 2004, pp 969-980.
21. Pollack IF, Hamilton RL, Burnham J, Holmes EJ, Finkelstein SD, Sposto R, Yates AJ, Boyett JM, Finlay JL: Impact of proliferation index on outcome in childhood malignant gliomas: results in an multi-institutional cohort. Neurosurgery 2002;50:1238-1244.
22. Campbell JW, Pollack IF, Martinez AJ, Shultz B: High-grade astrocytomas in children. Radiologically complete resection is associated with excellent long term prognosis. Neurosurgery 1996;38:258-264.
23. Phuphanich S, Edwards MSB, Levin VA, Vestnys PS, Wara WM, Davis RL, Wilson CB: Supratentorial malignant gliomas of childhood. Results of treatment with radiation therapy and chemotherapy. J Neurosurg 1984;60:495-499.
24. Pollack IF, Campbell JW, Hamilton RL, Martinez AJ, Bozik ME: Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer 1997;79:849-856.
25. Sposto R, Ertel IJ, Jenkin RDT, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D: The effectiveness of chemotherapy for treatment of high grade astrocytoma in children. Results of a randomized trial - A report from the Childrens Cancer Study Group. J Neurooncol 1989;7:165-177.
26. Sure U, Ruede D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi M: Determination of p53 mutations, EGFR overexpression and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 1997;56:782-789.
27. Zhang S, Feng X, Koga H, Ichikawa T, Abe S, Kumanishi T: p53 gene mutations in pontine gliomas of juvenile onset. Biochem Biophys Res Commun 1993;196:851-857.
28. Louis N, Rubio MP, Correa KM, Gusella JF, Von Deimling A: Molecular genetics of pediatric brain stem gliomas: application of PCR technique to small and archival tumor specimens. J Neuropathol Exp Neurol 1993;52:507-515.
29. Lang FF, Miller DC, Pistarody S: High frequency of p53 protein accumulation without p53 gene mutations in human juvenile pilocytic low grade and anaplastic astrocytomas. Oncogene 1994;9:949-954.
30. Carolyn AF, Irene F, Michael D, Eric AS, Petu CP, Lucy BR, Leslie S, Greta RB, Jachyn AB: p53 gene mutations in pediatric brain tumors. Med Pediatr Oncol 1995;25:431-436.
31. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
32. Chung RY, Whaley J, Kley N, Anderson K, Louis DN, Menon A, Hettlich C, Freiman R, Hedley-White ET, Martuza R, Jenkins R, Yanell D, Seizinger BR: TP53 gene mutation and chromosome 17 deletion in human astrocytomas. Genes Chromosomes Cancer 1991;3:323-331.
33. Cheng Y, Ng H-K, Ding M, Zhang S-F, Pang JC-S, Lo KW: Molecular analysis of microdissected de novo glioblastoma and paired astrocytic tumors. J Neuropathol Exp Neurol 1999;58:120-128.
34. Cheng Y, Ng H-K, Zhang S-F, Ding M, Pang JC-S, Zheng J, Poon WS: Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 1999;30:1284-1290.
35. Lang FF, Miller DC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-436.
36. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN: Molecular genetic correlates of p16, cdk4 and pRb immunohistochemistry in glioblastoma. J Neuropathol Exp Neurol 1998;57:122-130.
37. Ueki K, Ono Y, Henson JW, Elird JT, Von Deimling A, Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-153.
38. Korsmeyer S: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-886.
39. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
40. Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC: Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol (Berl) 1997;94:369-75.
41. Miyashita T, Harigai M, Hanada M, Reed K: Identification of a p53 - Dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-3135.
42. Ellison D, Steart PV, Gatter KC, Weller RO: Apoptosis in cerebral astrocytic tumors and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 1995;21:352-361.
43. Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L: Bcl-2 distribution in neuroepithelial tumors. An immunohistochemical study. J Neurooncol 1996;27:101-109.
44. Houbiers JG, Nijman HW, Vanden Burg H, et al: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072-2077.
45. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, et al: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997;57:304-309.